Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr tells Proactive's Stephen Gunnion the company ended its third quarter with $39 million cash in the bank, which will fund its pipeline of programs through to 2024.
He says the company, which is focused on women's oncology, had an active quarter with data from two of its ongoing gynecologic cancer trials. More catalysts lie ahead as 2022 draws to a close and into the new year, he adds.